2020
Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review.
Artukoglu BB, Li F, Szejko N, Bloch MH. Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32459404, DOI: 10.4088/jcp.19r12798.Peer-Reviewed Original ResearchConceptsTreatment of TDGreater score reductionPlacebo-controlled trialTardive dyskinesiaVitamin EPharmacologic treatmentTD symptomsScore reductionSystematic reviewPublication biasVesicular monoamine transporter 2 (VMAT2) inhibitorTardive dyskinesia treatmentVitamin E studiesTransporter 2 inhibitorsCalcium channel blockersDuration of treatmentTardive dyskinesia symptomsGreater reductionFixed-effects modelMedication classesHead trialsDyskinesia symptomsPrimary outcomePharmacologic agentsVMAT2 inhibitors
2019
Meta-analysis: Adulthood prevalence of Tourette syndrome
Levine JLS, Szejko N, Bloch MH. Meta-analysis: Adulthood prevalence of Tourette syndrome. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2019, 95: 109675. PMID: 31220521, DOI: 10.1016/j.pnpbp.2019.109675.Peer-Reviewed Original ResearchConceptsPrevalence of TSTourette syndromeRisk ratioCases of TSPrevalence estimatesLogit event rateAccurate prevalence estimatesTS prevalenceRemission criteriaTic symptomsFemale ratioPublic health decisionsOverall prevalencePsychiatric conditionsPublication biasCase identificationEvent ratesPrevalenceHealth decisionsLongitudinal studyAdultsSignificant differencesSyndromeTS casesTwo-thirds
2017
The efficacy of benzodiazepines as acute anxiolytics in children: A meta‐analysis
Kuang H, Johnson JA, Mulqueen JM, Bloch MH. The efficacy of benzodiazepines as acute anxiolytics in children: A meta‐analysis. Depression And Anxiety 2017, 34: 888-896. PMID: 28504861, PMCID: PMC5629100, DOI: 10.1002/da.22643.Peer-Reviewed Original ResearchConceptsEfficacy of benzodiazepinesPediatric patientsAnxiety disordersTolerability of benzodiazepinesRoom proceduresCurrent practice guidelinesStandardized mean differenceFunnel plot asymmetryOperating room proceduresProcedural settingsPediatric anxiety disordersTolerability analysisAcute managementBenzodiazepine treatmentStratified subgroupsPractice guidelinesControl groupAcute anxiolyticPublication biasAnxiolyticsBenzodiazepinesMean differencePatientsSpecific agentsAnxiety levels
2013
Meta-analysis: pharmacological treatment of pathological gambling
Bartley CA, Bloch MH. Meta-analysis: pharmacological treatment of pathological gambling. Expert Review Of Neurotherapeutics 2013, 13: 887-894. PMID: 23952195, DOI: 10.1586/14737175.2013.814938.Peer-Reviewed Original ResearchConceptsStandardized mean differenceReported efficacyPharmacological treatmentOpiate antagonistPathological gamblingPlacebo-controlled trialBenefits of medicationsCurrent trial dataFixed-effects modelTreat principleNon-significant effect sizeITT principlePharmacological agentsMeta-AnalysisTrial dataPublication biasSecondary analysisPlaceboMean differenceAntagonistTrialsMedicationsEfficacyYear of publicationEffect sizeMeta-analysis of LCPUFA Supplementation of Infant Formula and Visual Acuity
Qawasmi A, Landeros-Weisenberger A, Bloch MH. Meta-analysis of LCPUFA Supplementation of Infant Formula and Visual Acuity. Pediatrics 2013, 131: e262-e272. PMID: 23248232, PMCID: PMC3529943, DOI: 10.1542/peds.2012-0517.Peer-Reviewed Original ResearchConceptsInfant visual acuityMonths of ageLCPUFA supplementationVisual acuityInfant formulaTrial methodologic qualitySecondary subgroup analysisVisual acuity developmentVisual resolution acuityPrimary outcomeSubgroup analysisMethodologic qualityUnsupplemented infantsAcuity developmentNineteen studiesCurrent evidenceAcuityResolution acuityBirth statusSecondary analysisPublication biasMean differenceInfantsSupplementationSignificant heterogeneity
2012
Meta-analysis of Long-Chain Polyunsaturated Fatty Acid Supplementation of Formula and Infant Cognition
Qawasmi A, Landeros-Weisenberger A, Leckman JF, Bloch MH. Meta-analysis of Long-Chain Polyunsaturated Fatty Acid Supplementation of Formula and Infant Cognition. Pediatrics 2012, 129: 1141-1149. PMID: 22641753, PMCID: PMC3362904, DOI: 10.1542/peds.2011-2127.Peer-Reviewed Original ResearchConceptsLCPUFA supplementationClinical trialsInfant formulaLong-Chain Polyunsaturated Fatty Acid SupplementationBayley ScalesPolyunsaturated Fatty Acid SupplementationTrial methodologic qualityInfants fed formulaWeighted mean differenceSecondary subgroup analysisFatty acid supplementationMeasures of neurodevelopmentInfant Development scoresFed formulaPrimary outcomeSubgroup analysisUnsupplemented formulaMethodologic qualityInclusion criteriaPrematurity statusAcid supplementationSupplementation efficacySecondary analysisPublication biasMean differencePharmacologic Treatment of Repetitive Behaviors in Autism Spectrum Disorders: Evidence of Publication Bias
Carrasco M, Volkmar FR, Bloch MH. Pharmacologic Treatment of Repetitive Behaviors in Autism Spectrum Disorders: Evidence of Publication Bias. Pediatrics 2012, 129: e1301-e1310. PMID: 22529279, PMCID: PMC3340598, DOI: 10.1542/peds.2011-3285.Peer-Reviewed Original ResearchConceptsSerotonin receptor inhibitorsPublication biasTrial resultsPlacebo-controlled trialAutism spectrum disorderRepetitive behaviorsAvailable medicationsPatient agePharmacologic treatmentPrimary outcomeUnpublished trialsEgger's testReceptor inhibitorsMean improvementSpectrum disorderFunnel plotTrial designSecondary analysisTrial durationRating ScaleEfficacyTrialsTweedie's trimMedicationsTreatment
2011
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis
Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Molecular Psychiatry 2011, 17: 1272-1282. PMID: 21931319, PMCID: PMC3625950, DOI: 10.1038/mp.2011.100.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialMajor depressive disorderBaseline depression severityDepression severityPublication biasMethodological qualityGreater baseline depression severityDocosahexaenoic acidEicosapentaenoic acidTrial methodological qualityPrimary outcome measureNon-significant benefitTreatment of depressionLow methodological qualityFatty acid treatmentTreat analysisDepressive disorderMajor depressionSources of heterogeneityOutcome measuresClinical measuresTreatment efficacySystematic reviewSecondary analysisStudy participants